Finance

Lists
CSJA:FRA
CSL ADR
30,40 €
+1,33%
(+0,40) 1D
11-ноя., 21:36:00 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for CSJA...
Open
29,60 €
High
30,40 €
Low
29,60 €
Mkt. cap
96,78 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
43,40 €
52-wk low
12,70 €
No. of employees
29 миң
Open
29,60 €
High
30,40 €
Low
29,60 €
Mkt. cap
96,78 млд
Avg. vol.
0,00
Volume
0,00
52-wk high
43,40 €
52-wk low
12,70 €
No. of employees
29 миң
News stories
From web sources and news partners
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL ADR
CEOPaul McKenzie
Employees29 миң
Founded1916
HeadquartersМельбурн, Виктория, Австралия
SectorHealth Care
Industry-
Websitecsl.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
4,17 млд
4,17 млд
3,73 млд
3,73 млд
Cost of goods sold
1,94 млд
1,94 млд
1,93 млд
1,93 млд
Cost of revenue
1,94 млд
1,94 млд
1,93 млд
1,93 млд
Research and development expenses
300,00 млн
300,00 млн
311,50 млн
311,50 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
612,50 млн
612,50 млн
693,00 млн
693,00 млн
Operating expense
912,50 млн
912,50 млн
1,00 млд
1,00 млд
Total operating expenses
2,85 млд
2,85 млд
2,93 млд
2,93 млд
Operating income
1,32 млд
1,32 млд
802,00 млн
802,00 млн
Other non operating income
-
-
-
-
EBT including unusual items
190,00 млн
190,00 млн
-2,23 млд
-2,23 млд
EBT excluding unusual items
1,22 млд
1,22 млд
699,50 млн
699,50 млн
Income tax expense
47,00 млн
47,00 млн
-597,50 млн
-597,50 млн
Effective tax rate
24,74%
24,74%
26,75%
26,75%
Other operating expenses
-
-
-
-
Net income
200,50 млн
200,50 млн
-1,49 млд
-1,49 млд
Net profit margin
4,81%
4,81%
-39,92%
-39,92%
Earnings per share
-
-
-
-
Interest and investment income
9,00 млн
9,00 млн
6,00 млн
6,00 млн
Interest expense
-106,50 млн
-106,50 млн
-108,50 млн
-108,50 млн
Net interest expenses
-97,50 млн
-97,50 млн
-102,50 млн
-102,50 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,56 млд
1,56 млд
974,00 млн
974,00 млн
Gain or loss from assets sale
22,50 млн
22,50 млн
500,00 миң
500,00 миң
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору